![[logo] HealthTree Foundation](https://static.healthtree.org/icons/icon_spinner.svg){kind=icon}
![[logo] HealthTree Foundation](https://static.healthtree.org/logo_icon_only.svg){kind=icon}
Juvenile Myelomonocytic Leukemia
What is Juvenile Myelomonocytic Leukemia?
Juvenile Myelomonocytic Leukemia (JMML) is a rare and serious form of blood cancer that affects children, usually under the age of 4. It is characterized by the overproduction of white blood cells in the bone marrow, which can lead to severe anemia, infections, and other complications. JMML accounts for about 2% of all childhood leukemias and is difficult to treat. It often progresses rapidly and can be fatal if not treated promptly.
Types of Juvenile Myelomonocytic Leukemia
There are no specific types of Juvenile Myelomonocytic Leukemia. However, the disease can be categorized based on genetic mutations that are often associated with it. These include mutations in the PTPN11, NRAS, CBL, and KRAS genes. Each of these mutations can lead to different disease characteristics and responses to treatment.
Why do people get Juvenile Myelomonocytic Leukemia?
The exact cause of Juvenile Myelomonocytic Leukemia is not known. However, it is believed to be caused by a combination of genetic and environmental factors. Some children with JMML have certain genetic disorders, such as neurofibromatosis type 1 or Noonan syndrome, which increase their risk of developing the disease. Other factors that may contribute to the development of JMML include exposure to certain chemicals or radiation, a history of bone marrow or stem cell transplantation, and certain viral infections. However, in many cases, the cause of JMML remains unknown.
Who gets Juvenile Myelomonocytic Leukemia?
According to the National Cancer Institute, there will be an estimated ___ new cases of Juvenile Myelomonocytic Leukemia in 2023, making up ___% of all new cancer diagnoses. In 2020, there were an estimated ___ people living with Juvenile Myelomonocytic Leukemia in the United States. (you get this info from the NCI’s SEER data. Add the link to this data as a hyperlink on the text “National Cancer Institute”
Want to Learn More About Juvenile Myelomonocytic Leukemia?
Keep reading HealthTree for Juvenile Myelomonocytic Leukemia's 101 pages!
Juvenile Myelomonocytic Leukemia
What is Juvenile Myelomonocytic Leukemia?
Juvenile Myelomonocytic Leukemia (JMML) is a rare and serious form of blood cancer that affects children, usually under the age of 4. It is characterized by the overproduction of white blood cells in the bone marrow, which can lead to severe anemia, infections, and other complications. JMML accounts for about 2% of all childhood leukemias and is difficult to treat. It often progresses rapidly and can be fatal if not treated promptly.
Types of Juvenile Myelomonocytic Leukemia
There are no specific types of Juvenile Myelomonocytic Leukemia. However, the disease can be categorized based on genetic mutations that are often associated with it. These include mutations in the PTPN11, NRAS, CBL, and KRAS genes. Each of these mutations can lead to different disease characteristics and responses to treatment.
Why do people get Juvenile Myelomonocytic Leukemia?
The exact cause of Juvenile Myelomonocytic Leukemia is not known. However, it is believed to be caused by a combination of genetic and environmental factors. Some children with JMML have certain genetic disorders, such as neurofibromatosis type 1 or Noonan syndrome, which increase their risk of developing the disease. Other factors that may contribute to the development of JMML include exposure to certain chemicals or radiation, a history of bone marrow or stem cell transplantation, and certain viral infections. However, in many cases, the cause of JMML remains unknown.
Who gets Juvenile Myelomonocytic Leukemia?
According to the National Cancer Institute, there will be an estimated ___ new cases of Juvenile Myelomonocytic Leukemia in 2023, making up ___% of all new cancer diagnoses. In 2020, there were an estimated ___ people living with Juvenile Myelomonocytic Leukemia in the United States. (you get this info from the NCI’s SEER data. Add the link to this data as a hyperlink on the text “National Cancer Institute”
Want to Learn More About Juvenile Myelomonocytic Leukemia?
Keep reading HealthTree for Juvenile Myelomonocytic Leukemia's 101 pages!
Get the latest thought leadership on your Juvenile Myelomonocytic Leukemia delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.
HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.
Copyright © 2024 HealthTree Foundation. All rights reserved.
Tax ID 45-5354811